Interplay between Solid Tumors and Tumor Microenvironment.
extracellular matrix
metastasis
stromal cell
tumor heterogeneity
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
02
2022
accepted:
04
05
2022
entrez:
16
6
2022
pubmed:
17
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Over the past few decades, basic studies aimed at curing patients with cancer have been constantly evolving. A myriad of mechanistic studies on physiological changes and related factors in tumor growth and metastasis have been reported. Recently, several studies have been considerate to how tumors adapt to unfavorable environments, such as glucose deprivation, oxidative stress, hypoxic conditions, and immune responses. Tumors attempt to adapt to unfavorable environments with genetic or non-genetic changes, the alteration of metabolic signals, or the reconfiguration of their environment through migration to other organs. One of the distinct features in solid tumors is heterogeneity because their environments vary due to the characteristics of colony growth. For this reason, researchers are paying attention to the communication between growing tumors and neighboring environments, including stromal cells, immune cells, fibroblasts, and secreted molecules, such as proteins and RNAs. During cancer survival and progression, tumor cells undergo phenotype and molecular changes collectively referred to as cellular plasticity, which result from microenvironment signals, genetics and epigenetic alterations thereby contributing to tumor heterogeneity and therapy response. In this review, we herein discuss the adaptation process of tumors to adverse environments
Identifiants
pubmed: 35707536
doi: 10.3389/fimmu.2022.882718
pmc: PMC9189309
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
882718Informations de copyright
Copyright © 2022 Kim, Khadka and Seo.
Déclaration de conflit d'intérêts
Author DK was employed by NADIANBIO Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Curr Opin Cell Biol. 2017 Oct;48:47-53
pubmed: 28605656
Cell Biosci. 2011 Aug 31;1:29
pubmed: 21880137
Cancers (Basel). 2017 Jul 26;9(8):
pubmed: 28933725
Immunity. 2018 Feb 20;48(2):396-398
pubmed: 29466761
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Neoplasia. 2009 Dec;11(12):1264-71
pubmed: 20019834
Int J Biol Sci. 2018 Nov 13;14(14):2083-2093
pubmed: 30585271
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Exp Cell Res. 2016 Apr 10;343(1):73-81
pubmed: 26597760
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
Biochem Biophys Res Commun. 2018 May 5;499(2):374-380
pubmed: 29577899
Front Immunol. 2019 Aug 30;10:2035
pubmed: 31543877
Cell Res. 2020 Jun;30(6):492-506
pubmed: 32433595
Nat Commun. 2018 Dec 4;9(1):5150
pubmed: 30514914
Int J Mol Sci. 2018 Oct 04;19(10):
pubmed: 30287763
Cancer Lett. 2013 Nov 28;341(1):80-96
pubmed: 23376253
Cancer Cell. 2010 Feb 17;17(2):135-47
pubmed: 20138012
Hepatology. 2019 Jul;70(1):198-214
pubmed: 30810243
Clin Exp Metastasis. 2019 Jun;36(3):171-198
pubmed: 30972526
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Cell. 2020 Mar 16;37(3):421
pubmed: 32183954
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
Int J Biol Sci. 2011;7(5):651-8
pubmed: 21647333
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006536
pubmed: 22393533
Front Cell Dev Biol. 2019 Apr 24;7:60
pubmed: 31106200
Cell Rep. 2020 May 19;31(7):107628
pubmed: 32433953
Semin Radiat Oncol. 2009 Apr;19(2):106-11
pubmed: 19249648
Cancer Discov. 2019 Jul;9(7):837-851
pubmed: 30992279
Cancer Res. 2016 Oct 1;76(19):5597-5601
pubmed: 27634765
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
Nat Rev Immunol. 2012 Nov;12(11):749-61
pubmed: 23080391
Cell Res. 2020 Sep;30(9):745-762
pubmed: 32561858
Cell Mol Immunol. 2019 Jan;16(1):6-18
pubmed: 29628498
Phys Biol. 2016 Apr 29;13(3):036001
pubmed: 27125980
Cell Mol Immunol. 2019 Mar;16(3):242-249
pubmed: 30796351
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Stem Cells. 2009 Oct;27(10):2614-23
pubmed: 19650040
iScience. 2018 Jun 29;4:20-35
pubmed: 30240741
Oncoimmunology. 2018 Mar 13;7(7):e1440166
pubmed: 29900041
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Trends Immunol. 2007 Dec;28(12):519-24
pubmed: 17981504
Cell Cycle. 2017 Mar 19;16(6):533-535
pubmed: 28103135
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
Signal Transduct Target Ther. 2021 Feb 23;6(1):75
pubmed: 33619259
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183
pubmed: 27028474
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Cancers (Basel). 2021 Mar 18;13(6):
pubmed: 33803675
Immunity. 2020 May 19;52(5):856-871.e8
pubmed: 32289253
Front Oncol. 2021 Mar 08;11:596798
pubmed: 33763348
Adv Drug Deliv Rev. 2016 Feb 1;97:41-55
pubmed: 26743193
Cell Death Dis. 2019 Feb 22;10(3):182
pubmed: 30796204
Cancer Chemother Pharmacol. 2009 Mar;63(4):571-82
pubmed: 19083000
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Cancers (Basel). 2017 Jul 06;9(7):
pubmed: 28684679
Cancer Sci. 2017 Oct;108(10):1921-1926
pubmed: 28763139
Int J Mol Sci. 2016 Nov 01;17(11):
pubmed: 27809279
J Endocrinol. 2011 May;209(2):139-51
pubmed: 21307119
Tumour Biol. 2017 Mar;39(3):1010428317695920
pubmed: 28347239
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Immunity. 2016 Apr 19;44(4):913-923
pubmed: 27096320
World J Gastroenterol. 2012 Jun 21;18(23):2938-47
pubmed: 22736917
Immunology. 2009 Apr;126(4):458-65
pubmed: 19278419
Oncoimmunology. 2012 Mar 1;1(2):244-246
pubmed: 22720258
J Immunol. 2015 Feb 15;194(4):1389-94
pubmed: 25663676
Front Oncol. 2016 Jan 19;6:3
pubmed: 26835418
Cold Spring Harb Perspect Med. 2013 Jan 01;3(1):a006569
pubmed: 23085847
Cancers (Basel). 2016 Mar 15;8(3):
pubmed: 26999211
J Cell Biol. 2012 Feb 20;196(4):395-406
pubmed: 22351925
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1478-83
pubmed: 23766387
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Mol Cancer. 2019 Mar 4;18(1):34
pubmed: 30832661
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Front Pharmacol. 2012 Jul 17;3:140
pubmed: 22822400
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302
Carcinogenesis. 2018 Mar 8;39(3):397-406
pubmed: 29346528